AbbVie Inc (CHIX:4ABd) Stock News, Headlines & Updates
AbbVie Inc Stock News from GuruFocus
- 1
- 2
- 3
- 4
Jul 22, 2025
AbbVie Inc (ABBV) Empowers Women Entrepreneurs with The Confidence Project | ABBV stock news
GuruFocus News • 9:10am
BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project
PRNewswire • 8:00am
BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project | ABBV Stock News
GuruFocus News • 7:24am
Jul 15, 2025
AbbVie Inc (ABBV) Shares Down 3.06% on Jul 15
GuruFocus News • 12:09pm
Jul 11, 2025
Vanguard Group Inc. Expands Stake in AbbVie Inc. with Strategic Share Acquisition
GuruFocus News • 7:37pm
Jul 10, 2025
Wall Street Stunned: AbbVie Drops $700M on a Little-Known Indian Cancer Drug
Khac Phu Nguyen • 10:45am
AbbVie (ABBV) Secures Licensing Deal for Cancer Drug ISB 2001
GuruFocus News • 9:55am
AbbVie (ABBV) Secures Licensing Deal for Oncology Asset | ABBV Stock News
GuruFocus News • 7:02am
AbbVie (ABBV) Secures Exclusive Licensing for Innovative Therapy from IGI | ABBV Stock News
GuruFocus News • 7:01am
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
PRNewswire • 7:00am
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody | ABBV Stock News
GuruFocus News • 6:46am
Jul 03, 2025
AbbVie (ABBV) Revises Earnings Guidance Amid Expenses
GuruFocus News • 12:56pm
Jun 30, 2025
AbbVie (ABBV) to Acquire Capstan Therapeutics for $2.1 Billion
GuruFocus News • 9:00am
FDA Reviews AbbVie's SKINVIVE by JUVÉDERM® for Neck Line Treatment | ABBV stock news
GuruFocus News • 8:17am
AbbVie Inc (ABBV) Announces Upcoming Second-Quarter 2025 Earnings Call | ABBV stock news
GuruFocus News • 8:17am
AbbVie to Acquire Capstan Therapeutics: A Strategic Move in Immunology | ABBV stock news
GuruFocus News • 8:17am
U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
PRNewswire • 8:00am
AbbVie to Host Second-Quarter 2025 Earnings Conference Call
PRNewswire • 8:00am
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
PRNewswire • 8:00am
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology | ABBV Stock News
GuruFocus News • 7:46am
U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance | ABBV Stock News
GuruFocus News • 7:45am
AbbVie to Host Second-Quarter 2025 Earnings Conference Call | ABBV Stock News
GuruFocus News • 7:18am
Jun 20, 2025
AbbVie Inc (ABBV) Announces Quarterly Dividend Increase | ABBV stock news
GuruFocus News • 8:05am
AbbVie Declares Quarterly Dividend
PRNewswire • 8:00am
AbbVie (ABBV) Maintains $1.64 Quarterly Dividend
GuruFocus News • 7:57am
AbbVie Declares Quarterly Dividend | ABBV Stock News
GuruFocus News • 7:15am
Jun 18, 2025
AbbVie (ABBV) Sees Success with Migraine Drug Atogepant in Late-Stage Trial
GuruFocus News • 8:57am
AbbVie Inc (ABBV) Announces Positive Phase 3 Study Results for Migraine Treatment | ABBV stock news
GuruFocus News • 8:14am
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
PRNewswire • 7:00am
AbbVie (ABBV) Reports Positive Results from Migraine Study | ABBV Stock News
GuruFocus News • 6:46am
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention | ABBV St
GuruFocus News • 6:30am
Jun 17, 2025
AbbVie (ABBV) Faces Potential Challenges Amid U.S. Advertising Policy Changes
GuruFocus News • 10:56am
Jun 16, 2025
AbbVie (ABBV) and Genentech Report Phase III Study Results for Venclexta | ABBV Stock News
GuruFocus News • 11:16am
AbbVie (ABBV) Faces Setback in VERONA Study for Venclexta | ABBV Stock News
GuruFocus News • 11:15am
AbbVie (ABBV) Faces Setback with Leukemia Drug Trial
GuruFocus News • 9:56am
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
PRNewswire • 9:00am
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes | ABBV Stock News
GuruFocus News • 8:17am
AbbVie (ABBV) Phase 3 Trial on Myelodysplastic Syndrome Falls Short | ABBV Stock News
GuruFocus News • 8:17am
Jun 11, 2025
AbbVie (ABBV) Secures FDA Approval for Expanded Use of Mavyret
GuruFocus News • 12:57pm
AbbVie Inc (ABBV) Gains FDA Approval for Expanded Use of MAVYRET® | ABBV stock news
GuruFocus News • 12:01pm
- 1
- 2
- 3
- 4
Show
Entries
Headlines
Total 0- 1
No recent news